RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0037-1617770
Epilepsiebehandlung mit neuen Antiepileptika
Epilepsy treatment with new antiepileptic drugsPublikationsverlauf
Publikationsdatum:
11. Januar 2018 (online)
Zsuammenfassung
Die neuen Antiepileptika erweisen sich ähnlich gut wirksam wie die bisherigen klassischen Antiepileptika. Ihr Vorteil liegt in der besseren Verträglichkeit und geringeren Interaktion mit anderen Medikamenten. Bei therapieresistenten Anfällen kann bei zusätzlicher Behandlung mit den neuen Antiepileptika zwar häufig keine Anfallsfreiheit, aber doch bei vielen Patienten eine deutliche Anfallsreduktion erzielt werden. Wegen fehlender Langzeiterfahrung hinsichtlich von Nebenwirkungen und wegen der hohen Kosten werden die meisten neuen Antiepileptika vorerst nur als Mittel der zweiten Wahl eingesetzt.
Summary
The new antiepileptic drugs seem to be comparable effective to the conventional antiepileptic drugs. They show reduced problems with adverse effects and drug interactions. By add-on therapy of drug resistant seizures only rarely seizure freedom is achieved. However reduction of seizure frequency and seizure severity is often observed. Clinical application may be recommended up to now only as second choice as long as long-term experience of side effects in children are rare.
-
Literatur
- 1 Beydoun A. Monotherapy trials with gabapentinfor partial epilepsy. Epilepsia 1999; 40 (Suppl. 06) 13-6.
- 2 Biton V, Montouris GD, Ritter F. et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 1330-7.
- 3 Bourgeois BFD. Important pharmacokinetik properties of antiepileptic drugs. Epilepsia 1995; 36 (Suppl. 05) 1-7.
- 4 Dam M, Ekberg R, Löyning Y. A double-blind study comparing oxcarbazepin and carbamazepin in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6.
- 5 Elterman RD, Glauser TA, Wyllie E. et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52: 1338-44.
- 6 Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrogine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995; 91: 200-2.
- 7 Frank LM, Enlow T, Holmes GL. et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-9.
- 8 Glauser TA. Topiramate. Epilepsia 1999; 40 (Suppl. 05) 71-80.
- 9 Glauser TA, Clark PO, Strawsbury R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324-8.
- 10 Glauser TA, Sachdeo RC, Ritter FJ. et al. Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut sydnrome. Neurology 1999; 52: 1882-7.
- 11 Glauser T, Bebin M, Ritter F, Nohria V, Jensen C. Open-label efficacy and safety of levetiracetam in pediatric patients with partial onset seizures. Epilepsia. 1999 40. (Suppl 7).
- 12 Guerreiro M, Vigonius U, Pohlmann H. et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy res 1997; 27: 205-13.
- 13 Guerrini R, Dravet C, Genton P. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998b 39: 508-12.
- 14 Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999; 14: 71-4.
- 15 Krakow K, Otoul C, Sander JWAS. Long-term efficacy and tolerability of levetiracetam in refractory epilepsy. Neurology. 2000 54. (Suppl 3).
- 16 Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
- 17 Morris GL. Gabapentin. Epilepsia 1999; 40 (Suppl. 05) 63-70.
- 18 Motte J, Trevathan E, Arvidsson JFV. et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. New Engl J Med 1997; 337: 1807-12.
- 19 Pellock JM. Felbamate. Epilepsia 1999; 40 (Suppl. 05) 57-62.
- 20 Pellock JM, Appleton R. Use of new antiepileptic drugs in the teatment of childhood epilepsy. Epilepsia 1999; 40 (Suppl. 06) 29-38.
- 21 Pisani F, Oteri G, Russo MF. et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmaco-dynamic interaction. Epilepsia 1999; 40: 1141-6.
- 22 Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 1999; 40: 1471-83.
- 23 Schachter SC. Tiagabine. Epilepsia 1999; 40 (05) 17-22.
- 24 Schmidt D, Elger CE. Oxcarbazepin (Trileptal) – ein wirksames und gut verträgliches Medikament der ersten Wahl zur Behandlung fokaler Anfälle. Nervenarzt 2000; 71: 849-55.
- 25 Siemes H. Lamotrigin als Zusatztherapie bei schwierig zu behandelnden Epilepsien des Kindes- und Jugendalters. Päd Prax 1999; 56: 254-6.
- 26 Siemes H, Brandl U, Spohr HL. et al. Longterm follow-up study of vigabatrin in pretreated children with West Syndrome. Seizure 1998; 7: 293-7.
- 27 Siemes H, Blaise FD. Bourgeois Anfälle und Epilepsien bei Kindern und Jugendlichen. Stuttgart, New York: Thieme; 2001
- 28 Walker JE, Koon R. Carbamazepine versus valproate versus combined therapy for refractory partial complex seizueres with secondary generalization. Epilepsia 1998; 29: 693.
- 29 Wheless JW, Ng YT. Levetiracetam in Refractory Pediatric Epilepsy. J Child Neurol 2002; 17 (06) 413-5.
- 30 Wohlrab G, Boltshauser E, Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998; 29: 133-6.
- 31 Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu D. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10: 279-86.